$5.24
▲ +0.4% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Overview
52-week range
$1.74
$16
24% of range
Avg surprise (last 2)
+32.7%
Avg reaction (last 2)
-2.4%
0% positive
Latest IV / EM
296%
EM ±67.7% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.39 | — | — | -95.0% | -2.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.74 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.32 | $-0.39 | +17.9% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.20 | $-0.38 | +47.4% | — | -2.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.15 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.25 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.69 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.17 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.48 | -$0.32 | -50.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | — | $-8M | $-7M | $-8M | — | $-10M | $-12M |
| Net income | $-115M | — | $-27M | $-16M | $-7M | — | $-5M | $9M |
| EPS (diluted) | $-3.16 | — | $-0.74 | $-0.45 | $-0.20 | — | $-0.15 | $-0.25 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5M | $9M | $15M | $4M | $12M | $9M | $17M | $26M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $6M | $11M | $17M | $8M | $13M | $11M | $22M | $31M |
| Total assets | $70M | $77M | $90M | $81M | $87M | $86M | $98M | $108M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $381M | $295M | $185M | $150M | $141M | $134M | $149M | $154M |
| Total equity | $-312M | $-219M | $-96M | $-70M | $-54M | $-48M | $-51M | $-46M |